What РЕАМБЕРИН Treats: Main Uses and Benefits

This medication is commonly used to provide supportive therapeutic benefit in acute clinical scenarios marked by temporary physiological imbalance. Its therapeutic focus is aligned with managing conditions associated with metabolic acid-base imbalance.

This treatment is used for managing severe symptom clusters in critical care, including those related to acute systemic intoxication (such as ethanol or certain foodborne poisonings), severe metabolic acidosis (as seen in Diabetic Ketoacidosis), and symptoms linked to tissue hypoxia (often a complication of severe infectious diseases).

The medication provides support that helps ease the overall symptom burden when acute episodes create noticeable physiological strain. It assists with maintaining functional stability by supporting symptomatic management, offering relief that helps patients cope more steadily with difficult episodes.

---

Quick Fact: Focus on Acute Systemic Stress Management The treatment is applied in clinical settings that involve acute or unstable symptom patterns, offering support during phases of increased distress or discomfort associated with poisoning and metabolic crisis.

Official Eligibility Profile for РЕАМБЕРИН

Regulatory documentation defines strict eligibility rules for using РЕАМБЕРИН (Meglumine Sodium Succinate Solution for Infusion), focusing on metabolic state, organ function, and specific patient demographics.

Populations with Absolute Contraindications

The medicine must not be used in patients with:

• Hypersensitivity to the active substance or excipients.
• Severe Renal Impairment.
• Alkalosis (metabolic or compensated) or Hypernatremia (high blood sodium).
• Acute Cerebral Edema (brain swelling).

Age-Related Eligibility

• Infants under 1 year of age: Use is contraindicated or not recommended due to insufficient established regulatory data.
• Children and Adolescents (1 to 18 years): Use is permitted, but requires careful control and dosage calculation based on body weight.

Special Population and Condition Restrictions

• Pregnancy and Lactation: Use is not recommended or contraindicated unless the physician determines the benefits outweigh potential risks, as regulatory safety data are not fully established.
• Organ Function: Marked hepatic impairment and non-severe renal impairment require caution and close monitoring.
• Circulatory Status: Caution is required for patients with pre-existing cardiovascular disorders or acute circulatory insufficiency due to the infused volume.

Interactions with other medicines and products

This section describes the officially documented interaction patterns for РЕАМБЕРИН (Meglumine Sodium Succinate) based strictly on government regulatory documents.

Administration Restrictions and Incompatibilities

The primary restriction is the physical incompatibility of the infusion solution with highly alkaline solutions (solutions with a high pH, such as Sodium Bicarbonate solutions). Regulatory information stipulates that РЕАМБЕРИН must not be mixed with these substances in the same intravenous line or container to prevent chemical destabilization, making this a mandatory timing rule for administration separation.

Pharmacodynamic Interactions

Because the infusion contains essential electrolytes (Sodium Chloride, Potassium Chloride, and Magnesium Chloride), co-administration with other medicinal products can result in additive pharmacodynamic effects on the body’s internal balance. Specifically:

• Diuretics and Electrolyte-Losing Products: Co-administration may enhance effects on electrolyte status.
• Other Anti-Hypoxic Agents: Co-administration may result in an additive anti-hypoxic effect, reinforcing the drug’s general anti-hypoxic properties.

Pharmacokinetic Profile

The regulatory profile lists no explicitly contraindicated combinations based on pharmacological or pharmacokinetic interaction risk. Furthermore, due to the active component's rapid incorporation into the body’s natural metabolic pathways, no specific CYP450 enzyme-mediated or transporter-based interactions (e.g., P-gp) resulting in altered exposure ( AUC or Cmax) are documented in official regulatory labels.

Reamberin's pharmacodynamic mechanism is driven by its active component, succinate, which functions as a substrate antihypoxant. The succinate is delivered into cells, particularly within the mitochondria, where it acts as a key intermediate in the Krebs cycle (Citric Acid Cycle).

This engagement directly modulates molecular steps by influencing the rate of ATP synthesis and regulating metabolic flux through the respiratory chain. Simultaneously, succinate influences redox pathways by interacting with components of the endogenous antioxidant defense system, including ceruloplasmin and vitamin E. This interaction alters the cellular response to elevated mediator activity and modifies signaling sequences that influence the cellular redox state, particularly concerning free radical oxidation and lipid peroxidation.

As an infusion solution, Reamberin influences biological systems involving the regulation of ion and fluid metabolism. It affects the distribution and flow of ions and water, resulting in changes to plasma volume and osmotic pressure at a system level.

Administration Guidelines for РЕАМБЕРИН

This section outlines the administration procedures for the preparation, without discussing therapeutic rationale or effects. The product is a 1.5% solution for infusion, supplied ready-to-use in polymer containers, and is administered exclusively via intravenous (IV) drip infusion.

Procedural and Dosing Rules

Administration Scope	Adult Rules	Pediatric Rules (Aged ≥ 1 Year)
Route & Preparation	IV Drip Infusion; supplied as ready-to-use 1.5% solution.	IV Drip Infusion; supplied as ready-to-use 1.5% solution.
Standard Daily Dose	An average of 10 mL/kg of body weight.	6–10 mL/kg of body weight per day.
Infusion Flow Rate	1–4.5 mL/min (up to 90 drops per minute).	3–4 mL/min (rate caution is necessary).
Maximum Course Length	Treatment should not exceed 11 days.	Treatment should not exceed 11 days.

The established procedures include strict control of the infusion flow rate during administration. For adult patients, the maximum daily volume is determined by a weight-dependent formula. Special attention is required during administration to children and the elderly. Timing in relation to meals is not a specified administration requirement for this IV therapy. No formal missed-dose instructions are explicitly documented in the standard product documentation.

Research Evidence / Overview of studies for РЕАМБЕРИН

This section provides a factual summary of the types of research and clinical trials that have examined the medicinal preparation РЕАМБЕРИН (Meglumine Sodium Succinate), as documented in official and peer-reviewed sources. It focuses on the structure of the evidence and what has been observed in study populations, without giving any clinical advice or making claims about individual outcomes.

---

Evidence for Use in Acute Metabolic Crisis

Research has explored the use of this infusion in research exploring its application during acute metabolic imbalances, a context commonly seen in critical care. Specifically, the drug was evaluated in short-term Randomized Controlled Trials (RCTs) and multi-center clinical studies research examined two core areas: conditions where the research goal was to correct metabolic acidosis in critically ill patients and conditions where the research goal was to manage Diabetic Ketoacidosis (DKA).

For critically ill adult patients with low blood pH (metabolic acidosis), research examined how quickly key acid-base markers in the blood returned to the normal range. Studies monitored outcomes related to systemic or functional imbalance, such as changes in serum bicarbonate levels, and also reported patterns in the length of a patient's stay in the Intensive Care Unit (ICU).

What remains uncertain is the overall long-term patient follow-up after these acute crises; the data is primarily focused on the immediate stabilization phase. Research limitations include the need for broader confirmation of findings across all severities and types of metabolic crisis.

---

Evidence for Use in Systemic Stress and Organ Support

Studies have also examined the use of РЕАМБЕРИН in conditions associated with acute or disruptive episodes linked to toxicity or organ strain. Controlled clinical trials and comparative studies were conducted to explore the drug's role in contexts such as acute systemic intoxication (like ethanol poisoning) and in managing hepatic dysfunction (such as viral or drug-induced liver injury).

For acute systemic intoxication, research focused on patients with depressed consciousness and metabolic disturbances. Studies monitored outcomes related to systemic or functional imbalance, such as changes in consciousness level (e.g., Glasgow Coma Score) and changes in metabolic parameters. The findings help contextualize how patients reported their experience and how metabolic parameters changed during the treatment period.

A key research limitation is that much of the available evidence regarding organ support is primarily from controlled trials focused on biochemical shifts, and there is limited information for long-term outcomes related to functional liver health or post-treatment recurrence.

---

Evidence Focused on Functional Outcomes and Specific Conditions

The medicine was studied for its use in conditions where research explores its relevance to compromised oxygen use, known as tissue hypoxia. Smaller, controlled clinical trials have examined the medicine's role in contexts such as chronic cerebral ischemia and conditions associated with cognitive deficits.

These studies examined specific functional measures and patient-reported outcomes describing perceived discomfort. For instance, outcomes related to daily functioning or activity level, such as performance on cognitive tests, were monitored in the observed populations. The data show patterns related to changes in specific cognitive metrics over a short course of observation and treatment.

---

Long-Term Studies and Follow-up

Research to date has been primarily conducted during research scenarios focusing on episodes where symptoms become more noticeable and in acute clinical settings. Consequently, the long-term effects are not fully established, and there is limited information for long-term outcomes or durability of any observed physiological shifts.

Common questions about РЕАМБЕРИН (FAQ)

Q: What specific conditions is РЕАМБЕРИН indicated to treat?

Regulatory documents list the use of РЕАМБЕРИН in complex therapy for acute disorders. The formal indications include conditions involving acute endogenous intoxication (poisoning originating within the body) and severe hypoxia (when tissues are deprived of adequate oxygen).

Q: What is the difference between РЕАМБЕРИН and other common infusion solutions?

The difference lies in the active component. Unlike simple electrolyte or saline solutions, official documents classify РЕАМБЕРИН as a detoxifying and anti-hypoxic medicinal agent. Its unique composition includes meglumine sodium succinate, which is responsible for its metabolic effects.

Q: What are the most common side effects listed for РЕАМБЕРИН?

The official product information lists several observed adverse reactions, although most lack a specific frequency classification. The observed effects listed include temporary changes such as a metallic taste in the mouth, headache, an increased heart rate (tachycardia), or a feeling of warmth or fever.

Q: Can РЕАМБЕРИН be given at the same time as other IV medications?

Official guidance on chemical compatibility states that the solution is restricted from being mixed with highly alkaline solutions, such as Sodium Bicarbonate, in the same intravenous line or container.

Q: What are the general considerations for using РЕАМБЕРИН in older adults?

Official administration guidelines indicate that special attention and careful monitoring are required when the medicine is administered to elderly patients. The regulatory instructions require that the infusion rate be strictly controlled during the process.

Q: Has РЕАМБЕРИН been approved or studied in other countries, like the U.S. or E.U.?

The primary regulatory approval and registration for this medicine are provided by the government regulatory body of the Russian Federation. Official information indicates the product is not currently listed in the standard drug registries for the United States (FDA) or the European Union (EMA).

Q: Is РЕАМБЕРИН considered a vitamin or mineral supplement?

No. Regulatory documents classify РЕАМБЕРИН as a prescription medicinal product. It belongs to the pharmacological group of detoxifying agents and anti-hypoxic agents, distinguishing it from common vitamins or mineral supplements.

Q: Why do doctors prescribe РЕАМБЕРИН for many different issues?

The medicine works by targeting fundamental processes within the cell. Its active component, succinate, is key in the Krebs cycle and is designed to restore cellular energy. This systemic action helps tissues counteract oxygen deprivation (hypoxia) in various acute situations across the body.

Q: What is the typical fluid volume of a РЕАМБЕРИН infusion?

Official guidelines specify the dose in relation to body weight rather than a fixed volume. The standard daily amount for adult patients is typically calculated as an average of 10 mL/kg of body weight.

Q: Why do people sometimes say РЕАМБЕРИН helps with energy levels?

The official purpose of the drug is described as supporting tissues by facilitating cellular energy restoration. The active succinate component is known to stimulate core energy pathways, which is consistent with the drug’s official purpose.

Q: Are there specific monitoring requirements (like blood tests) associated with РЕАМБЕРИН treatment?

Yes. Due to the drug’s role in balancing the body's internal chemistry, official guidance notes the need for control and monitoring of the patient's acid-base status. This monitoring is considered necessary, especially in patients with pre-existing conditions.

Q: Do official documents mention the risk of fluid overload with РЕАМБЕРИН?

Official guidance advises caution for patients with cardiovascular disorders or acute circulatory insufficiency. This precaution is related to the possibility of increased blood volume due to the volume of fluid being infused.

Q: What is the meaning of 'metabolic acidosis' in relation to РЕАМБЕРИН?

Metabolic acidosis is a serious disturbance where the body's fluids become overly acidic. Research examined the use of РЕАМБЕРИН to help correct key acid-base markers in the blood during acute metabolic crises.

Q: Can РЕАМБЕРИН be used to help recovery after surgery?

While not listed as a specific surgical recovery agent, the official indications include use in complex therapy for acute disorders involving tissue hypoxia and intoxication. These indications are relevant in contexts such as severe systemic stress.

Q: Is РЕАМБЕРИН an antibiotic or an antiviral medicine?

No, it is not. Official regulatory classification places РЕАМБЕРИН in the pharmacological categories of a detoxifying agent and an anti-hypoxic agent.

Q: Is it normal to feel warmth or flushing during the infusion of РЕАМБЕРИН?

Yes, a feeling of warmth or chills is listed among the systemic effects observed. These temporary effects are noted in the official product information as being related to the rate at which the infusion is administered.

Q: What should I do if I notice an unexpected reaction during the РЕАМБЕРИН drip?

Regulatory instructions state this medicine must be administered under medical supervision in a clinical setting. Any unexpected or serious reactions should be communicated immediately to the administering health professional.

Q: Does РЕАМБЕРИН interact with high blood pressure medicines?

The medicine contains essential electrolytes. Official interaction guidance notes that co-administration with other products, such as diuretics (a type of blood pressure medicine), may result in additive effects on the body’s electrolyte balance.

Q: Are there any common foods or supplements that interact with РЕАМБЕРИН?

Official regulatory documents list no specific interactions with common foods or dietary supplements. The interactions described relate primarily to other co-administered medicinal products and highly alkaline IV solutions.

Q: How quickly can one expect to see any effects from the drug?

The medicine is administered directly into the bloodstream via intravenous infusion. Research has focused on its use during the immediate stabilization phase in acute clinical settings, where it is observed to rapidly influence acid-base markers.

Q: Does РЕАМБЕРИН help with immunity or inflammation?

Official information notes that the active component influences redox pathways. It interacts with components of the endogenous antioxidant defense system, which alters cellular response to elevated mediator activity linked to stress and inflammation.

Q: Is РЕАМБЕРИН a prescription-only medicine?

Yes. РЕАМБЕРИН is officially classified as a prescription-only medicine. Its complex administration procedure and strict monitoring requirements reflect the requirement for administration only under the direct supervision of a qualified healthcare professional.

Q: Is it possible to use РЕАМБЕРИН at home instead of in a clinic?

Due to the required administration method and safety profile, it is necessary to use this medicine in a clinical setting. Administration is required to be performed under direct medical supervision with continuous monitoring of the patient's metabolic status.

Q: Does РЕАМБЕРИН affect blood sugar levels?

Research has examined the use of the infusion in complex conditions that involve blood sugar regulation. Specifically, studies explored its application in managing Diabetic Ketoacidosis (DKA), which involves complex clinical management and control of blood sugar and metabolic status.

How to Store and Dispose of РЕАМБЕРИН?

Official regulatory information strictly defines the conditions necessary for storing and disposing of РЕАМБЕРИН (Meglumine Sodium Succinate Solution for Infusion) to maintain its integrity.

---

Required Storage Conditions

Requirement	Specific Instruction
Temperature	Store at a temperature no higher than 25 C
Protection	Must be protected from light
Container Rule	Keep the solution in the original package
Prohibition	Do not freeze the solution
Safety	Must be stored out of the sight and reach of children

---

Disposal Instructions

To comply with environmental protection rules, unused or expired РЕАМБЕРИН must not be disposed of into wastewater or general household trash. All remaining solution and packaging must be discarded strictly according to local legal requirements for pharmaceutical waste disposal, as mandated by regulatory authorities. The product's shelf-life is 5 years when stored under the specified conditions.